These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 22878367)

  • 1. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor.
    Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG
    Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
    Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
    Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma.
    Anforth RM; Blumetti TC; Kefford RF; Sharma R; Scolyer RA; Kossard S; Long GV; Fernandez-Peñas P
    Br J Dermatol; 2012 Nov; 167(5):1153-60. PubMed ID: 22804352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse skin reactions induced by BRAF inhibitors: a systematic review].
    Sibaud V; Lamant L; Maisongrosse V; Delord JP
    Ann Dermatol Venereol; 2013; 140(8-9):510-20. PubMed ID: 24034635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming metastatic melanoma with BRAF inhibitors.
    Hong S; Hong S; Han SB
    Arch Pharm Res; 2011 May; 34(5):699-701. PubMed ID: 21656352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma.
    Park JJ; Hawryluk EB; Tahan SR; Flaherty K; Kim CC
    JAMA Dermatol; 2014 Mar; 150(3):307-11. PubMed ID: 24352115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of BRAF inhibitor-induced hyperkeratosis.
    Battley JE; Lenihan E; Redmond HP; Murphy M; Power DG
    Acta Oncol; 2013 May; 52(4):874-7. PubMed ID: 22998476
    [No Abstract]   [Full Text] [Related]  

  • 10. [New treatment options for metastatic melanoma].
    Tietze JK; Berking C
    Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
    [No Abstract]   [Full Text] [Related]  

  • 11. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
    Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
    Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.
    Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P
    Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete Cytologic Remission of V600E BRAF-Mutant Melanoma-Associated Leptomeningeal Carcinomatosis Upon Treatment With Dabrafenib.
    Wilgenhof S; Neyns B
    J Clin Oncol; 2015 Oct; 33(28):e109-11. PubMed ID: 24733801
    [No Abstract]   [Full Text] [Related]  

  • 14. Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
    Vanneste L; Wolter P; Van den Oord JJ; Stas M; Garmyn M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):61-8. PubMed ID: 24661317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted molecular therapies (except immunotherapy)].
    Roux J; Pages C; Lebbé C
    Bull Cancer; 2014 Dec; 101 Suppl 2():S25-36. PubMed ID: 25776764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
    Menzies AM; Long GV
    Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency.
    Hong DS; Vence L; Falchook G; Radvanyi LG; Liu C; Goodman V; Legos JJ; Blackman S; Scarmadio A; Kurzrock R; Lizee G; Hwu P
    Clin Cancer Res; 2012 Apr; 18(8):2326-35. PubMed ID: 22355009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma.
    Dika E; Patrizi A; Ribero S; Fanti PA; Starace M; Melotti B; Sperandi F; Piraccini BM
    Eur J Dermatol; 2016 Jun; 26(3):232-9. PubMed ID: 27019511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potassium iodide in successful treatment of erythema nodosum-like lesions induced by combination therapy with dabrafenib and trametinib.
    Sawada H; Kanehisa F; Katoh N; Asai J
    J Dermatol; 2020 Jan; 47(1):e7-e8. PubMed ID: 31587335
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
    Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
    J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.